Search Result

Isoforms Recommended:	VEGFR2/KDR/Flk-1

Results for "

VEGFR2

" in MCE Product Catalog:

By Targets:	Akt (1) Antibiotic (1) Apoptosis (45) Aurora Kinase (5) Autophagy (25) Bacterial (2) Bcl-2 Family (1) Bcr-Abl (3) c-Fms (7) c-Kit (25) c-Met/HGFR (13) Casein Kinase (2) CDK (2) Checkpoint Kinase (Chk) (1) Complement System (2) Dihydrofolate reductase (DHFR) (2) Discoidin Domain Receptor (2) Drug Metabolite (2) EGFR (8) Endogenous Metabolite (1) Ephrin Receptor (1) ERK (2) FAK (1) Ferroptosis (3) FGFR (29) FLT3 (21) Fungal (2) GSK-3 (2) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (2) HSV (1) IAP (1) IKK (1) Integrin (2) IRE1 (4) JAK (2) LRRK2 (1) MAP3K (1) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (2) Mitophagy (4) Mixed Lineage Kinase (2) mTOR (1) NF-κB (1) PDGFR (47) PERK (1) PI3K (2) PROTACs (2) Raf (8) Reactive Oxygen Species (2) RET (8) Src (13) Survivin (1) Syk (1) TAM Receptor (8) Topoisomerase (2) Trk Receptor (4) VEGFR (175)
By Research Areas:	Cancer (176) Cardiovascular Disease (10) Endocrinology (1) Infection (4) Inflammation/Immunology (16) Metabolic Disease (2)

By Targets:

Akt (1)

Antibiotic (1)

Apoptosis (45)

Aurora Kinase (5)

Autophagy (25)

Bacterial (2)

Bcl-2 Family (1)

Bcr-Abl (3)

c-Fms (7)

c-Kit (25)

c-Met/HGFR (13)

Casein Kinase (2)

CDK (2)

Checkpoint Kinase (Chk) (1)

Complement System (2)

Dihydrofolate reductase (DHFR) (2)

Discoidin Domain Receptor (2)

Drug Metabolite (2)

EGFR (8)

Endogenous Metabolite (1)

Ephrin Receptor (1)

ERK (2)

FAK (1)

Ferroptosis (3)

FGFR (29)

FLT3 (21)

Fungal (2)

GSK-3 (2)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (2)

HSV (1)

IAP (1)

IKK (1)

Integrin (2)

IRE1 (4)

JAK (2)

LRRK2 (1)

MAP3K (1)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (2)

Mitophagy (4)

Mixed Lineage Kinase (2)

mTOR (1)

NF-κB (1)

PDGFR (47)

PERK (1)

PI3K (2)

PROTACs (2)

Raf (8)

Reactive Oxygen Species (2)

RET (8)

Src (13)

Survivin (1)

Syk (1)

TAM Receptor (8)

Topoisomerase (2)

Trk Receptor (4)

VEGFR (175)

By Research Areas:

Cancer (176)

Cardiovascular Disease (10)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (16)

Metabolic Disease (2)

192

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-103002

SU5408
VEGFR2 Kinase Inhibitor I
VEGFR Cardiovascular Disease

SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC₅₀ of 70 nM.

SU5408 VEGFR2 Kinase Inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-145849

VEGFR2-IN-1	VEGFR	Cancer
VEGFR2-IN-1 is a potent and selective *VEGFR2* inhibitor (IC₅₀=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and *VEGFR2* inhibition.

HY-147133

VEGFR2-IN-2
VEGFR Cancer

VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

VEGFR2-IN-2	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis.

HY-148040

VEGFR-2-IN-29
VEGFR Cancer

VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC₅₀ of 16.5 nM.
HY-18625

VEGFR-2-IN-5
VEGFR Cancer

VEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69.
HY-18625A

VEGFR-2-IN-5 hydrochloride
VEGFR Cancer

VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69.
HY-144804

VEGFR-2-IN-17
VEGFR Cancer

VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities.
HY-144803

VEGFR-2-IN-16
VEGFR Cancer

VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities.
HY-147902

VEGFR-2-IN-24
VEGFR Cancer

VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research.
HY-131658

VEGFR-2-IN-6
VEGFR Others

VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.

VEGFR-2-IN-29	VEGFR	Cancer
VEGFR-2-IN-29 (Compound 5) is a *VEGFR-2* inhibitor with an IC₅₀ of 16.5 nM.

VEGFR-2-IN-5	VEGFR	Cancer
VEGFR-2-IN-5 is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69.

VEGFR-2-IN-5 hydrochloride	VEGFR	Cancer
VEGFR-2-IN-5 hydrochloride is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69.

VEGFR-2-IN-17	VEGFR	Cancer
VEGFR-2-IN-17 (Compound 15a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities.

VEGFR-2-IN-16	VEGFR	Cancer
VEGFR-2-IN-16 (Compound 15b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities.

VEGFR-2-IN-24	VEGFR	Cancer
VEGFR-2-IN-24 is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research.

VEGFR-2-IN-6	VEGFR	Others
VEGFR-2-IN-6 (example 64) is a *VEGFR2* inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF^V600E and BRAF^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase.

HY-147800

VEGFR-2-IN-21
VEGFR Cancer

VEGFR-2-IN-21 (Compound 5d) is a potent VEGFR-2 inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity.
HY-146236

VEGFR-2-IN-27
VEGFR Cancer

VEGFR-2-IN-27 (compound 7a) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer.

VEGFR-2-IN-21	VEGFR	Cancer
VEGFR-2-IN-21 (Compound 5d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity.

VEGFR-2-IN-27	VEGFR	Cancer
VEGFR-2-IN-27 (compound 7a) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer.

HY-146491

VEGFR-2/BRAF-IN-1	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF^V600E and BRAF^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase.

HY-145856

VEGFR-2-IN-11	VEGFR Apoptosis	Cancer
VEGFR-2-IN-11 (Compound 8h) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis.

HY-146229

VEGFR-2-IN-25
VEGFR Cancer

VEGFR-2-IN-25 (compound 5d) is a highly potent VEGFR-2 inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer.
HY-139822

VEGFR-2-IN-10
VEGFR Cancer

VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.

VEGFR-2-IN-25	VEGFR	Cancer
VEGFR-2-IN-25 (compound 5d) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer.

VEGFR-2-IN-10	VEGFR	Cancer
VEGFR-2-IN-10 exhibits increased antiangiogenic potency (IC₅₀ = 0.7 μM) against VEGF-induced *VEGFR2* phosphorylation without cytotoxic effects.

HY-147926

VEGFR-2-IN-28	VEGFR Apoptosis	Cancer
VEGFR-2-IN-28 (compound 12c) is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.83 µM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity.

HY-144805

VEGFR-2-IN-18	VEGFR Apoptosis	Cancer
VEGFR-2-IN-18 (Compound 15d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities.

HY-144795

VEGFR-2-IN-14
VEGFR Apoptosis Cancer

VEGFR-2-IN-14 (Compound 5) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis.
HY-144796

VEGFR-2-IN-15
VEGFR Apoptosis Cancer

VEGFR-2-IN-15 (Compound 14b) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis.

VEGFR-2-IN-14	VEGFR Apoptosis	Cancer
VEGFR-2-IN-14 (Compound 5) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis.

VEGFR-2-IN-15	VEGFR Apoptosis	Cancer
VEGFR-2-IN-15 (Compound 14b) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis.

HY-146367

VEGFR-2-IN-19	VEGFR Apoptosis Reactive Oxygen Species	Cancer
VEGFR-2-IN-19 (Compound 15b) is a potent *VEGFR2* inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent.

HY-144754

VEGFR-2-IN-13	VEGFR Apoptosis	Cancer
VEGFR-2-IN-13 (Compound 19a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 3.4 nM. VEGFR-2-IN-13 disrupts the HepG2 cell cycle by arresting the G2/M phase and induces apoptosis.

HY-101628

VEGFR-2-IN-9
KDR-in-4
VEGFR Cardiovascular Disease

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

VEGFR-2-IN-9 KDR-in-4	VEGFR	Cardiovascular Disease
VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC₅₀ of 7 nM.

HY-149024

VEGFR-2-IN-23	VEGFR Apoptosis MDM-2/p53	Cancer
VEGFR-2-IN-23 (compound 11b) is a potent and selective *VEGFR-2* inhibitor with an IC₅₀ value of 0.34 nM. VEGFR-2-IN-23 shows antitumor activity. VEGFR-2-IN-23 induces apoptosis and cell cycle arrest at G1 phase.

HY-146230

VEGFR-2-IN-26	VEGFR	Cancer
VEGFR-2-IN-26 (compound 5h) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 15.5 nM. VEGFR-2-IN-26 has good antiproliferative activity against the leukemic, non-small lung, CNS, ovarian, renal, prostate and breast cancer cells.

HY-151969

VEGFR-2-IN-30	VEGFR	Cancer
VEGFR-2-IN-30 is a VEGFR-2 inhibitor (IC₅₀: 66 nM). VEGFR-2-IN-30 also inhibits PDGFR, EGFR and FGFR1 with IC₅₀s of 180, 98, 82 nM respectively. VEGFR-2-IN-30 arrests cancer cell at S-phase and induces early and late apoptosis.

HY-145864

VEGFR-2-IN-12	VEGFR	Cancer
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI₅₀=1.6 µM). VEGFR-2-IN-12 has antitumor activity.

HY-151459

VEGFR-2/DHFR-IN-2	VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal	Cancer Infection
VEGFR-2/DHFR-IN-2 (compound 5b) is an inhibitor of *VEGFR-2* and DHFR with IC₅₀s of 0.623 and 9.085 μM, respectively. VEGFR-2/DHFR-IN-2 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC₅₀ values of 3.59-8.38 μM. VEGFR-2/DHFR-IN-2 can be used for the research of cancer.

HY-151458

VEGFR-2/DHFR-IN-1	VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal	Cancer Infection
VEGFR-2/DHFR-IN-1 (compound 8b) is an inhibitor of *VEGFR-2* and DHFR with IC₅₀s of 0.384 and 7.881 μM, respectively. VEGFR-2/DHFR-IN-1 shows good antibacterial activities against Escherichia coli, Streptococcus faecalis, Salmonella enterica, MSSA and MRSA with MIC values of 16, 16, 16, 8, and 16 μg/mL, respectively. VEGFR-2/DHFR-IN-1 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC₅₀ values of 2.97-7.12 μM. VEGFR-2/DHFR-IN-1 can be used for the research of cancer.

HY-147779

VEGFR-2-IN-20
VEGFR Cancer

VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of VEGFR. VEGFR-2-IN-20 has the potential for the research of cancer diseases.

VEGFR-2-IN-20	VEGFR	Cancer
VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of *VEGFR. VEGFR-2*-IN-20 has the potential for the research of cancer diseases.

HY-146368

*PROTAC VEGFR-2* degrader-1**	PROTACs VEGFR	Cancer
PROTAC VEGFR-2 degrader-1（PROTAC-1）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC₅₀> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC₅₀> 100 μM).

HY-146369

*PROTAC VEGFR-2* degrader-2**	PROTACs VEGFR	Cancer
PROTAC VEGFR-2 degrader-2（PROTAC-4）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC₅₀> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC₅₀> 100μM).

HY-12572

*TIE-2/VEGFR-2* kinase-IN-2**	VEGFR	Cancer
TIE-2/VEGFR-2 kinase-IN-2 is a potent dual *VEGFR2* and *Tie-2* inhibitor with pIC₅₀ values of 8.61 and 8.56, respectively. TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research.

HY-151635

*PI3K/VEGFR2-IN-1*	PI3K VEGFR Apoptosis	Cancer
PI3K/VEGFR2-IN-1 is a potent dual *PI3K/VEGFR2* inhibitor with IC₅₀ values of 2.21 and 68 μM for PI3K and VEGFR2, respectively. PI3K/VEGFR2-IN-1 induces apoptosis. PI3K/VEGFR2-IN-1 can be used in research of cancer.

HY-125741

GW768505A free base	VEGFR	Cancer
GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and *Tie-2, with a pIC₅₀ of 7.81 for VEGFR2*. GW768505A free base has anti-angiogenic activity。

HY-112294

*TIE-2/VEGFR-2* kinase-IN-1**	VEGFR	Cancer Inflammation/Immunology Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis.

HY-21289

SU5205
VEGFR Cancer

SU5205 is an inhibitor of VEGFR2 (FLK-1), with an IC₅₀ of 9.6 μM.
HY-P99808

Pulocimab
VEGFR Cancer

Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.

SU5205	VEGFR	Cancer
SU5205 is an inhibitor of VEGFR2 (FLK-1), with an IC₅₀ of 9.6 μM.

Pulocimab	VEGFR	Cancer
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Cancer
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-21292

SU5214
SU4949
VEGFR Cancer

SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has IC₅₀s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively.
HY-146539

HDAC-IN-35
HDAC VEGFR Cancer

HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively.
HY-100419

BFH772
VEGFR Cancer

BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM.

SU5214 SU4949	VEGFR	Cancer
SU5214 is a potent *VEGFR2* inhibitor extracted from patent US5834504A, SU5214, has IC₅₀s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively.

HDAC-IN-35	HDAC VEGFR	Cancer
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and *VEGFR-2* inhibitor, with IC₅₀ values of 0.166 and 13.2 µM for HDAC6 and *VEGFR-2*, respectively.

BFH772	VEGFR	Cancer
BFH772 is a potent oral *VEGFR2* inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC₅₀ value of 3 nM.

HY-10527C

Telatinib mesylate Bay 57-9352 mesylate	VEGFR PDGFR c-Kit	Cancer
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active *VEGFR2, VEGFR3, PDGFα, and c-Kit* inhibitor with IC₅₀s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.

HY-12018

Vatalanib dihydrochloride PTK787 dihydrochloride; CGP-797870 dihydrochloride; ZK-222584 dihydrochloride	VEGFR Apoptosis	Cancer
Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-120200

YF-452	VEGFR	Cancer Cardiovascular Disease
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-P9920

Ramucirumab	VEGFR	Cancer
Ramucirumab is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor.

HY-109020

Acrizanib
LHA510
VEGFR Others

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC₅₀ of 17.4 nM for BaF3-VEGFR-2.

HY-P99826

Pegdinetanib BMS-844203; CT-322	VEGFR	Cancer
Pegdinetanib (BMS-844203; CT-322) is a selective *VEGFR-2* (VEGFR) inhibitor with K_ds of 11 nM and 250 nM and IC₅₀s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity.

HY-12038

Ki8751
VEGFR Cancer

Ki8751 is a potent VEGFR2 inhibitor with an IC₅₀ of 0.9 nM.

HY-19986

AAL993	VEGFR	Cancer Cardiovascular Disease
IC₅₀s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties.

HY-147243

Ansornitinib ANG-3070	VEGFR PDGFR	Inflammation/Immunology Cardiovascular Disease
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases.

HY-12047

Ponatinib AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, *VEGFR2, FGFR1, and Src*, respectively.

HY-N8342

Rhamnazin	VEGFR	Cancer Inflammation/Immunology
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.

HY-10203

Vatalanib free base PTK787 free base; PTK/ZK free base; CGP-79787 free base; ZK-222584 free base	VEGFR	Cancer
Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-10248

RAF265
CHIR-265
Raf VEGFR Autophagy Apoptosis Cancer

RAF265 is a potent and orally active RAF/VEGFR2 inhibitor.

HY-13302

CP-547632	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.

HY-13302B

CP-547632 hydrochloride	VEGFR FGFR	Cancer
CP-547632 hydrochloride is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy.

HY-108766

Ponatinib hydrochloride AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Cancer
Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, *VEGFR2, FGFR1, and Src*, respectively.

HY-15467

ZM323881
VEGFR Cancer

ZM323881 is a potent and selective VEGFR2 inhibitor with an IC₅₀ of less than 2 nM.
HY-15467A

ZM323881 hydrochloride
VEGFR Cancer

ZM323881 hydrochloride is a potent and selective VEGFR2 inhibitor with an IC₅₀ of less than 2 nM.

HY-13645

Henatinib	VEGFR c-Kit PDGFR	Cancer
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities. Henatinib inhibits the activity of *VEGFR-2, c-kit, PDGFR* with IC₅₀ values of 0.6 nM, 3.3 nM and 41.5 nM, respectively. Henatinib significantly inhibits VEGFR-2 phosphorylation and its downstream signal pathway in human umbilical vein endothelial cells (HUVECs).

HY-13302C

CP-547632 TFA	VEGFR FGFR	Cancer
CP-547632 TFA is an orally active, ATP-competitive and potent *VEGFR-2* and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-108933

JK-P3	VEGFR FGFR	Cancer
JK-P3 is a potent and pan *VEGFR2* inhibitor, with IC₅₀s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity.

HY-15992

BIBF 1202
VEGFR Cancer

BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC₅₀ of 62 nM.
HY-100394

NVP-BAW2881
BAW2881
VEGFR Endocrinology Cancer

NVP-BAW2881 (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 4 nM.
HY-15333

ZK-261991
VEGFR Inflammation/Immunology

ZK-261991 is an orally active VEGFR tyrosine kinase inhibitor with an IC₅₀ of 5 nM for VEGFR2.
HY-108443

DMH4
VEGFR Cancer

DMH4 is a potent and selective inhibitor of VEGFR2 with an IC₅₀ of 0.16 µM.
HY-147694

c-Met-IN-11
c-Met/HGFR VEGFR Cancer

c-Met-IN-11 (compound 3) is a potent c-MET and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively.
HY-136209

SU5208
VEGFR Cancer

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

HY-108444

(Z)-FeCP-oxindole	VEGFR	Cancer
(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC₅₀ value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC₅₀ less than 1 μM.

HY-126319

SU5204
VEGFR EGFR Cancer

SU5204, a tyrosine kinase inhibitor, has IC₅₀s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and *Ang2/Tie2* pathways.

HY-P99516

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells.

HY-19326

SU1498
AG 1498; Tyrphostin SU 1498
VEGFR Cancer Inflammation/Immunology

SU1498 (AG 1498) is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC₅₀ of value of 700 nM.
HY-U00437

Pz-1
RET VEGFR Cancer Cardiovascular Disease

Pz-1 is a potent RET and VEGFR2 inhibitor with IC₅₀s of less than 1 nM for both wild type kinases.
HY-16265

JI-101
Ephrin Receptor PDGFR VEGFR Cardiovascular Disease Cancer

JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.
HY-12060

KRN-633
VEGFR Cancer

KRN-633 is a potent VEGFR inhibitor with IC₅₀s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
HY-13068

Golvatinib
E-7050
c-Met/HGFR VEGFR Cancer

Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-10407

SU 5402	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively.

HY-150027

Multi-kinase-IN-3	VEGFR PDGFR	Cancer
Multi-kinase-IN-3 (compound 2) is a potent angiokinase inhibitor. Multi-kinase-IN-3 shows inhibition activity against *VEGFR-2* and PDGFRβ, with IC₅₀ values of 58.3 and 55 nM, respectively.

HY-18317

JNJ-38158471	VEGFR RET c-Kit	Cancer
JNJ-38158471 is a well tolerated, orally available, highly selective *VEGFR-2* inhibitor, with an IC₅₀ of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC₅₀s of 180 and 500 nM, respectively.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively.*

HY-144075

JAK-IN-19	JAK	Inflammation/Immunology
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ *pIC₅₀*=7.2 and HLF Eotaxin pIC₅₀=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC₅₀=7.0, Aurora B pIC₅₀=5.8).

HY-N0883

Gamabufotalin Gamabufagin	VEGFR	Cancer
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-16025

EOC317
ACTB-1003
FGFR VEGFR Cancer

EOC317 (ACTB-1003) is an oral kinase inhibitor with IC₅₀s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.

HY-124526

Chiauranib Ibcasertib; CS2164	VEGFR PDGFR c-Kit Aurora Kinase c-Fms	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, *VEGFR2, VEGFR3, PDGFRα* and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.

HY-10372

PP121
mTOR PDGFR VEGFR Src Apoptosis Cancer

PP121 is a multi-targeted kinase inhibitor with IC₅₀s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.
HY-10501

SU14813
PDGFR VEGFR c-Kit Cancer

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
HY-10501A

SU14813 maleate
PDGFR VEGFR c-Kit Cancer

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-143491

VS 8	VEGFR Apoptosis Reactive Oxygen Species	Cancer
VS 8 (Compound VS 8) is a potent, orally active *VEGFR-2* inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells).

HY-10497

BMS-794833
c-Met/HGFR VEGFR Cancer

BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC₅₀s of 15 and 1.7 nM, respectively.

HY-N0135

Tanshinone IIA Dan Shen ketone	VEGFR	Cardiovascular Disease Cancer
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-107145A

Ningetinib	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, *VEGFR2* and Axl, respectively.

HY-10527

Telatinib Bay 57-9352	c-Kit PDGFR VEGFR	Cancer
Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of *VEGFR2, VEGFR3, PDGFα, and c-Kit* with IC₅₀s of 6, 4, 15 and 1 nM, respectively.

HY-107145

Ningetinib Tosylate	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, *VEGFR2* and Axl, respectively.

HY-U00002

ZD-4190	VEGFR EGFR	Cancer
ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.

HY-18318

Takeda-6D	Raf VEGFR PERK	Cancer
Takeda-6D (compound 6d) is an orally active and potent *BRAF/VEGFR2* inhibitor, with IC₅₀ values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of *ERK1/2* phosphorylation. Takeda-6D shows antitumor activity.

HY-10321

PD173074	FGFR VEGFR Apoptosis	Cancer
PD173074 is a potent FGFR1 inhibitor with an IC₅₀ of 25 nM and also inhibits *VEGFR2* with an IC₅₀ of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-145023

RET-IN-5	RET	Cancer
RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC₅₀s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18).

HY-18179

AZD2932	PDGFR VEGFR FLT3 c-Kit	Cancer
AZD2932 is a potent and multi-targeted kinase inhibitor *VEGFR2, PDGFβ, Flt-3* and c-Kit with IC₅₀s of 8, 4, 7 and 9 nM in cell assay, respectively.

HY-13342AS

Apatinib-d8 free base YN968D1-d₈ free base	Src VEGFR Autophagy c-Kit RET	Cancer
Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

HY-15992S

BIBF 1202-13C,d3	VEGFR	Cancer
BIBF 1202-¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-N3001

Isolinderalactone	VEGFR Bcl-2 Family Survivin IAP	Cancer
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of *VEGFR2* activation in endothelial cells. Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi

HY-10065

Axitinib AG-013736	VEGFR PDGFR	Cancer
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

HY-111138

CZC-8004 CZC-00008004	EGFR VEGFR	Cancer
CZC-8004 (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 can bind a range of tyrosine kinases, including *EGFR* and *VEGFR2* with IC₅₀ values of 650 and 437 nM, respectively.

HY-13023

AMG-Tie2-1
VEGFR Cancer

AMG-Tie2-1 is an inhibitor of tunica interna endothelial cell kinase 2 (Tie2) with an IC₅₀ of 1 nM. AMG-Tie2-1 is a VEGFR2 inhibitor with an IC₅₀ of 3 nM.

HY-12009

Pazopanib Hydrochloride GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10991

MGCD-265 analog	c-Met/HGFR VEGFR Apoptosis	Cancer
MGCD-265 analog is a potent and oral active inhibitor of c-Met and *VEGFR2* tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.

HY-10337

Brivanib BMS-540215	VEGFR Autophagy	Cancer
Brivanib (BMS-540215) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.

HY-15506

TAK-593	PDGFR VEGFR	Cancer
TAK-593 is a potent *VEGFR* and PDGFR family inhibitor with IC₅₀s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.

HY-12686

5Z-7-Oxozeaenol FR148083; L783279; LL-Z 1640-2	MAP3K VEGFR Antibiotic	Infection Inflammation/Immunology
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-119757

Tyrphostin AG1433 SU1433; AG1433	PDGFR VEGFR	Cancer
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC₅₀s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation.

HY-120640

BMS-605541	VEGFR PDGFR	Cancer
BMS-605541 is a selective and orally active inhibitor of *VEGFR-2* kinase with an IC₅₀ value of 23 nM and K_i value of 49 nM. BMS-605541 inhibits the activity of Flk-1, *VEGFR-1* and PDGFR-β with IC₅₀ values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research.

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, *VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers *apoptosis*.

HY-10208

Pazopanib GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-15391

Lucitanib E-3810	VEGFR FGFR	Cancer
Lucitanib (E-3810) is a novel dual inhibitor of *VEGFR* and FGFR, potently and selectively inhibits *VEGFR1, VEGFR2, VEGFR3, FGFR1* and *FGFR2* with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human *anti-VEGFR2* monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer.

HY-10977A

Tivozanib hydrochloride hydrate AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate	VEGFR	Cancer
Tivozanib hydrochloride hydrate is a selective and orally active VEGFR tyrosine kinase inhibitor with IC₅₀ of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).

HY-10260B

Vandetanib hydrochloride ZD6474 hydrochloride	VEGFR Autophagy Apoptosis	Cancer
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM).

HY-10260

Vandetanib ZD6474	VEGFR Autophagy Apoptosis	Cancer
Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM).

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-10260A

Vandetanib trifluoroacetate ZD6474 trifluoroacetate	VEGFR Autophagy Apoptosis	Cancer
Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM).

HY-12044

Cabozantinib S-malate XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits *VEGFR2, c-Met, Kit, Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10336

Brivanib (alaninate) BMS-582664	VEGFR Autophagy	Cancer
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ.

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, *VEGFR-2* and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer.

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-147714

FGFR3-IN-2	FGFR VEGFR	Cancer
FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor, with IC₅₀s of 4.1 nM and 570 nM for FGFR3 and *VEGFR2, respectively. FGFR*3-IN-2 can be used for the research of bladder cancer.

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts.

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-16961

Sitravatinib MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Cancer Inflammation/Immunology
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

HY-10977

Tivozanib AV-951; KRN951	VEGFR	Cancer
Tivozanib (AV-951; KRN951) is a selective and orally active VEGFR tyrosine kinase inhibitor with IC₅₀ of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib has the potential for the research of metastatic renal cell carcinoma (RCC) ^[1].

HY-B0791

Altiratinib DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, *TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3* respectively.

HY-10255A

Sunitinib SU 11248	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for *VEGFR2* and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

HY-10542

GW 5074	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

HY-10208S

Pazopanib-d6 GW786034-d₆	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-112234

L-Sepiapterin Sepiapterin	Endogenous Metabolite	Cancer
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70^S6K-dependent VEGFR-2 expression.

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Cancer Inflammation/Immunology
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10255

Sunitinib Malate SU 11248 Malate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for *VEGFR2* and PDGFRβ, respectively. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.

HY-10260S

Vandetanib-d6 ZD6474-d₆	VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-50905S

Dovitinib-d8	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-12076

BMS 777607 BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases.

HY-10260S1

Vandetanib-d4	VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-108263A

(S)-3-Hydroxy Midostaurin (S)-CGP52421	FLT3 Drug Metabolite	Cancer
(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with IC₅₀ values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et). (S)-3-Hydroxy Midostaurin is a minor metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (S)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).

HY-10065S

Axitinib 13CD3 AG-013736-¹³C，d₃	VEGFR PDGFR	Cancer
Axitinib-¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Metabolic Disease Cardiovascular Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits *VEGF* signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.

HY-10255AS

Sunitinib-d10 SU 11248-d₁₀	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib-d₁₀ is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-112292A

GW806742X hydrochloride	Mixed Lineage Kinase VEGFR	Cancer
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against *VEGFR2* (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.

HY-112292

GW806742X	Mixed Lineage Kinase VEGFR	Others
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against *VEGFR2* (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis.

HY-10987A

ENMD-2076	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-10255AS1

Sunitinib-d4	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10065S1

Axitinib-d3 AG-013736-d₃	VEGFR	Cancer
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively.

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway.

HY-10987

ENMD-2076 Tartrate	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-50905

Dovitinib CHIR-258; TKI258	FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC₅₀s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, *VEGFR1/VEGFR2/VEGFR3* and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity.

HY-12009S

Pazopanib-13C,d3 hydrochloride GW786034-¹³C,d₃ hydrochloride	VEGFR PDGFR Autophagy c-Fms FGFR c-Kit	Cancer
Pazopanib-¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10208S1

Pazopanib-13C,d3 GW786034-¹³C,d₃	VEGFR PDGFR Autophagy FGFR c-Kit	Cancer
Pazopanib-¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-138696

Zanzalintinib XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, *VEGFR2, AXL* and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research.

HY-10185

TG 100572 Hydrochloride	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-146138

EGFR-IN-57	EGFR VEGFR Casein Kinase Topoisomerase Microtubule/Tubulin Apoptosis	Cancer
EGFR-IN-57 (Compound 25a) is a potent, orally active *EGFR-TK* inhibitor with an IC₅₀ of 0.054 µM. EGFR-IN-57 also inhibits *VEGFR-2, CK2α, topoisomerase IIβ* and tubulin polymerization with IC₅₀ values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis.

HY-13016A

Cabozantinib hydrochloride XL184 hydrochloride; BMS-907351 hydrochloride	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib hydrochloride is a potent and orally active inhibitor of *VEGFR2* and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, *TIE2, and FLT3* (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.

HY-13016

Cabozantinib XL184; BMS-907351	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib is a potent and orally active inhibitor of *VEGFR2* and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, *TIE2, and FLT3* (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell *apoptosis*.

HY-10251

BMS-599626 AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and *HER2* inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy.

HY-139590A

Zeteletinib hemiadipate BOS-172738 hemiadipate; DS-5010 hemiadipate	RET PDGFR	Cancer
Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RET^V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity.

HY-10408

Ki20227	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, *VEGFR2* (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.

HY-10201

Sorafenib Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.

HY-112780

UC2288	MDM-2/p53	Cancer
UC2288 is a novel, cell-permeable, and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 decreases p21 mRNA expression independently of p53, and attenuates p21 protein levels with minimal effect on p21 protein stability. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM.

HY-12010

BMS-599626 Hydrochloride AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and *HER2* inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy.

HY-139590

Zeteletinib BOS-172738; DS-5010	RET PDGFR	Cancer
Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RET^V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity.

HY-10201A

Sorafenib Tosylate Bay 43-9006 Tosylate	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for *VEGFR2, VEGFR3, PDGFRβ, FLT3* and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator.

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, *LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin.

HY-151945

TRK II-IN-1	Trk Receptor FLT3 VEGFR RET	Cancer
TRK II-IN-1 is a potent type II TRK inhibitor, with IC₅₀s of 3.3, 6.4, 4.3 and 9.4 nM, for TRKA/B/C and TRKA^G667C, respectively. TRK II-IN-1 also inhibits FLT3, RET, and *VEGFR2* with IC₅₀s of 1.3, 9.9, and 71.1 nM, respectively. TRK II-IN-1 can be used for the research of TRK driven cancers.

HY-10032

PF 477736 PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a *Chk2* inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over *VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret* (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo.

HY-116624

MAZ51	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity.

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10186

TG 100801	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10201S2

Sorafenib-13C,d3	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib-¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-N3127

Orobol	Casein Kinase PI3K VEGFR	Metabolic Disease
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ).

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC₅₀=0.041 μM) and modest potency against CDK4, *VEGF-R2, and FGF-R2* (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer.

HY-10799

EG00229	Complement System	Cancer
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.

HY-B0062

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, *VEGFR1/2/3* and PDGFRα/β, respectively.

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2.

HY-15813

FIIN-1 FGFR irreversible inhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective FGFR inhibitor. FIIN-1 binds to *FGFR1/2/3/4* and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.

HY-112306

Ripretinib DCC-2618	c-Kit PDGFR FLT3 VEGFR Apoptosis	Cancer
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis.

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Cancer Infection Inflammation/Immunology
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the *HIF-1α/VEGF/VEGFR-2* signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, *Erk1/2* and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).

Cat. No.	Product Name	Target	Research Area

HY-106374

Elpamotide	Peptides	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer.

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts.

Cat. No.	Product Name	Target	Research Area

HY-P99808

Pulocimab
VEGFR Cancer

Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers.

HY-P9920

Ramucirumab	VEGFR	Cancer
Ramucirumab is a human *VEGFR-2* antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor.

HY-P99826

Pegdinetanib BMS-844203; CT-322	VEGFR	Cancer
Pegdinetanib (BMS-844203; CT-322) is a selective *VEGFR-2* (VEGFR) inhibitor with K_ds of 11 nM and 250 nM and IC₅₀s of 16 nM and 240 nM for human and murine VEGFR-2, respectively. Pegdinetanib does not bind to VEGFR-1 or VEGFR-3. Pegdinetanib has antitumor activity.

HY-P99516

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells.

HY-P99768

Olinvacimab TTAC-0001	VEGFR	Cancer
Olinvacimab (TTAC-0001) is a fully human *anti-VEGFR2* monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a K_d value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer.

Cat. No.	Product Name	Target	Category

HY-N7177

Hydroxytanshinone IIA	Drug Metabolite VEGFR	Quinones Naphthalene Quinones Classification of Application Fields Disease Research Fields Cancer Source classification Plants Labiatae Hemistepta lyrata
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-N8342

Rhamnazin	VEGFR	Structural Classification Phenols Polyphenols Combretum erythrophyllum Sond. Combretaceae Plants Source classification
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.

HY-N2666

5α-Hydroxycostic acid	VEGFR	Terpenoids Other Terpenoids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Compositae Erythrina burttii Baker f.
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and *Ang2/Tie2* pathways.

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Phenols Monophenols Antibiotics Macrolide Antibiotics Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively.*

HY-N0883

Gamabufotalin Gamabufagin	VEGFR	Steroids Classification of Application Fields Disease Research Fields Cancer Source classification Animals
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-N0135

Tanshinone IIA Dan Shen ketone	VEGFR	Terpenoids Diterpenoids Quinones Naphthalene Quinones Classification of Application Fields Disease Research Fields Cancer Source classification Plants Labiatae Hemistepta lyrata
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-N3001

Isolinderalactone	VEGFR Bcl-2 Family Survivin IAP	Terpenoids Sesquiterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Lauraceae Lindera aggregata (Sims) Kosterm.
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of *VEGFR2* activation in endothelial cells. Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi

HY-12686

5Z-7-Oxozeaenol FR148083; L783279; LL-Z 1640-2	MAP3K VEGFR Antibiotic	Monophenols Phenols Structural Classification Natural Products Microorganisms Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-112234

L-Sepiapterin Sepiapterin	Endogenous Metabolite	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70^S6K-dependent VEGFR-2 expression.

HY-N3127

Orobol	Casein Kinase PI3K VEGFR	Flavonoids Isoflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Glycine max (L.) merr
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ).

Species:	Human (9) Rhesus Macaque (1) Rat (2) Mouse (4) Cynomolgus (1)
Tag:	His (9) Avi (2) Fc (8)
Source:	HEK293 (17)

Cat. No.	Product Name	Species	Source

HY-P71421

VEGFR-2 Protein, Human (HEK293, His-Avi) VEGFR2; VEGF R2; Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1	Human	HEK293

HY-P73481

VEGFR-2 Protein, Rat (HEK293, Fc)
Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309
Rat HEK293

HY-P70552

VEGFR-2 Protein, Human (745a.a, HEK293, His) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293

HY-P70635

VEGFR-2 Protein, Human (745a.a, HEK293, Fc) Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2	Human	HEK293

HY-P72429

VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc)
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; NYK; CD309
Mouse HEK293
HY-P73476

VEGFR-2 Protein, Human (327a.a, HEK293, Fc)
Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309
Human HEK293
HY-P73477

VEGFR-2 Protein, Human (208a.a, HEK293, Fc)
Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309
Human HEK293
HY-P73480

VEGFR-2 Protein, Mouse (762a.a, HEK293, Fc)
Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309
Mouse HEK293
HY-P73530

VEGFR-2 Protein, Human (764a.a, HEK293, His)
Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; FLK-1; CD309
Human HEK293
HY-P78697

VEGFR-2 Protein, Rhesus macaque (HEK293, His)
KDR; CD309; FLK1; VEGFR; VEGFR2
Rhesus Macaque HEK293
HY-P78536

VEGFR-2 Protein, Human (HEK293, mFc)
CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73
Human HEK293
HY-P700850

VEGFR-2 Protein, Human (Biotinylated, HEK293, mFc)
CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73
Human HEK293
HY-P78231

VEGFR-2 Protein, Human (Biotinylated, HEK293, His-Avi)
CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73
Human HEK293
HY-P74470

VEGFR-2 Protein, Rat (HEK293, His)
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309
Rat HEK293
HY-P74471

VEGFR-2 Protein, Mouse (HEK293, His)
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309
Mouse HEK293
HY-P74473

VEGFR-2 Protein, Cynomolgus (HEK293, His)
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309
Cynomolgus HEK293
HY-P74472

VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His)
Vascular endothelial growth factor receptor 2; VEGFR-2; FLK-1; CD309
Mouse HEK293

Cat. No.	Product Name

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

HY-15992S

BIBF 1202-13C,d3

BIBF 1202-¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202. BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10065S

Axitinib 13CD3
Axitinib-¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib-¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10208S1

Pazopanib-13C,d3
Pazopanib-¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

VEGFR2

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products